Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

NCT05431179 is registered in ClinicalTrials.gov with Oncternal Therapeutics, Inc as lead sponsor.

NCT NCT05431179
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05431179 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Zilovertamab (an ROR1 Antibody) Plus Ibrutinib Versus Ibrutinib Plus Placebo in Subjects With Relapsed or Refractory Mantle Cell Lymphoma
Lead sponsor
Oncternal Therapeutics, Inc
Phase
Phase 3
Overall status
Withdrawn
Start date
March 31, 2023
Completion date
December 31, 2026
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

immune system diseases, immunoproliferative disorders, lymphatic diseases, lymphoma, lymphoma, b-cell, lymphoma, mantle-cell, lymphoma, non-hodgkin, lymphoproliferative disorders